

Take a closer look



## MORE IN ONE

The established efficacy and tolerability of lacosamide... now in a **single daily dose**<sup>1</sup>

ONCE-DAILY  
**Motpoly XR**<sup>™</sup>  
(lacosamide) extended-release capsules



Partial-onset seizures



Juggling work and child care



Juan, 31  
For illustration purposes only.

For younger adults with partial-onset seizures with busier lifestyles, like Juan, consider **once-daily MOTPOLY XR**

- Steady 24-hour delivery with fewer fluctuations
- Proven XR bead technology achieves once-daily dosing
- Bioequivalent to lacosamide at steady-state blood levels

### INDICATION

MOTPOLY XR is indicated for adults and pediatric patients weighing at least 50 kg for treatment of partial-onset seizures and adjunctive therapy in the treatment of primary generalized tonic-clonic seizures.

**References:** 1. Data on file. Aucta Pharmaceuticals; 2022. 2. Samsonsen C, Reimers A, Bråthen G, et al. Nonadherence to treatment causing acute hospitalizations in people with epilepsy: an observational, prospective study. *Epilepsia*. 2014;55(11):e125-e128. 3. Mendorf S, Prell T, Schönenberg A. Detecting reasons for nonadherence to medication in adults with epilepsy: a review of self-report measures and key predictors. *J Clin Med*. 2022;11(15):4308.

Please see full Prescribing Information enclosed and Important Safety Information inside.



©2024 Aucta Pharmaceuticals, Inc. July 2024 033-0012

Take a closer look at...



## Busy Young Adults With Partial-Onset and PGTC Seizures

Consider once-daily MOTPOLY XR for young adults who may benefit from once-daily dosing



Sheila, 28  
For illustration purposes only.

For your busy young adult patients with **partial-onset seizures** or **PGTC seizures**, juggling work, home, kids, and the stress of everyday life can be challenging.

**Simplifying** their regimen by reducing their number of daily doses can make a difference!

### Make the switch to once-daily MOTPOLY XR

The established efficacy and tolerability of lacosamide... now in a **single daily dose**



MOTPOLY XR comes as a **100-mg, 150-mg, and 200-mg capsule**

### INDICATION

MOTPOLY XR is indicated for adults and pediatric patients weighing at least 50 kg for treatment of partial-onset seizures and adjunctive therapy in the treatment of primary generalized tonic-clonic seizures.

### IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

- Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.

PGTC=primary generalized tonic-clonic.

Please see additional Important Safety Information inside.

ONCE-DAILY  
**Motpoly XR**<sup>™</sup>  
(lacosamide) extended-release capsules

## Take a closer look




### Missed antiepileptic drug (AED) intake: a major obstacle to optimal epilepsy care and a common cause of breakthrough seizures, particularly in young adults<sup>2</sup>

#### Factors that may lead to reduced adherence in young adult patients:

- A busier lifestyle<sup>3</sup>
- Reduced beliefs in the necessity of medication<sup>3</sup>
- Coping difficulties<sup>2</sup>
- Immature attitudes about illness<sup>2</sup>
- Irregular lifestyle with use of alcohol<sup>2</sup>

#### Young adult age is an important risk factor for nonadherence<sup>2</sup>

##### Extent of nonadherence in hospitalized patients for seizures\*



\*Study included 282 consecutive admissions with epilepsy hospitalized for single or serial seizures during 44 months. Mean age was 49.5 years (range 16-91).<sup>2</sup>

Nonadherence was defined as probable when the concentration/dose (C/D) ratio at admission was 50 -75% of the control C/D ratio, and as definite when it was <50%. Each patient served as his or her own control. Steady-state, drug-fasting, control C/D ratios were obtained at scheduled outpatient appointments and controlled for co-medication.

Chris, 32

For illustration purposes only.

## IMPORTANT SAFETY INFORMATION

### WARNINGS AND PRECAUTIONS (cont)

- MOTPOLY XR may cause dizziness and ataxia in patients. Advise patients not to operate machinery or motor vehicles until they know how MOTPOLY XR affects them.
- Obtain ECG before beginning MOTPOLY XR, and after titration to steady-state maintenance dose in patients with underlying proarrhythmic conditions or on concomitant medications that affect cardiac conduction. Closely monitor these patients.
- MOTPOLY XR may cause syncope.
- Gradually withdraw MOTPOLY XR to minimize the potential of increased seizure frequency.
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/multi-organ hypersensitivity has been reported and can be life-threatening or fatal. If signs or symptoms are present, immediately evaluate the patient. Discontinue MOTPOLY XR if there is no alternative etiology.

### MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in adults ( $\geq 10\%$  and greater than placebo) are diplopia, headache, dizziness, nausea, and somnolence.

### USE IN SPECIFIC POPULATIONS:

- Dose adjustment is recommended for severe renal impairment and mild or moderate hepatic impairment. Consider dose reduction in patients with renal or hepatic impairment taking strong inhibitors of CYP3A4 and CYP2C9.
- Use is not recommended in severe hepatic impairment.
- Based on animal data, MOTPOLY XR may cause fetal harm if used in pregnancy.

ONCE-DAILY  
**Motpoly XR**<sup>TM</sup>  
(lacosamide) extended-release capsules

Please see additional full Prescribing Information.